Pharma had held minority stake in 2019 spinout of mAb, now in Phase III for atrial fibrillation and cancer-associated thrombosis

The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff

German pharma aiming to plug revenue hole as Xarelto nears patent cliff

Plus: Priority review for Orchard’s ex vivo gene therapy and more from BioNTech, Broken String and FDA

Plus Vicore gains on IPF data and updates from Acrivon, BioAtla, Novadip and more

Safety results and efficacy signals from Phase II readouts send Bayer’s asundexian and BMS’s milvexian

With MyoKardia deal, BMS doubles its CV pipeline, diversifies beyond cancer